Assessment of Lung Transplant Recipients Within The Scope of International Classification of Functioning, Disability and Health

Sponsor
Ankara City Hospital Bilkent (Other)
Overall Status
Completed
CT.gov ID
NCT05376605
Collaborator
(none)
27
1
9.5
2.9

Study Details

Study Description

Brief Summary

This study was aimed to evaluate the patients undergoing lung transplantation under the International Classification of Functionality, Disability and Health (ICF) and to examine the relationships between the age at which lung transplant recipients were transplanted and recipients' comorbidity levels and body structure and functions, activity and participation level.

Condition or Disease Intervention/Treatment Phase
  • Other: assessment

Detailed Description

After lung transplantation, many complications related to various reasons are observed in patients in the long term. In this study, the severity of fatigue, limitation of daily living activities, kinesophobia, impaired sleep quality, anxiety and depression level, fragility level, balance and functional capacity in lung transplant recipients; investigators aimed to examine the relationship between the age at which the patient was transplanted and the level of comorbidity. Although there are studies on comorbidities, quality of life, daily living activities and participation level, anxiety and depression level, sleep quality, balance and physical fitness level in lung transplant recipients, kinesiophobia upper extremity functional performance in patients who have undergone lung transplantation surgery, COVID-19 infection There are no studies evaluating the anxiety associated with the disease. No study evaluating body structure functions, activity and participation level based on ICF in lung transplantation has been encountered. In our study, patients with at least 3 months past lung transplantation and without orthopedic and mental problems will be evaluated. It will be made as a single evaluation. The last pulmonary function test results of the patients, comorbidity conditions, fatigue, respiratory quality of life, coronavirus anxiety status, sleep quality, kinesophobia will be evaluated by questionnaires. Lower extremity dynamic balance and mobility will be evaluated with 1 minute sit-to-stand test, timed up and go test. Upper extremity functionality will be evaluated with a 6-minute pegboard and ring test.

Study Design

Study Type:
Observational
Actual Enrollment :
27 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
ICF-Based Assessment in Lung Transplant Recipients
Actual Study Start Date :
Jan 27, 2021
Actual Primary Completion Date :
Nov 11, 2021
Actual Study Completion Date :
Nov 11, 2021

Arms and Interventions

Arm Intervention/Treatment
lung transplant

Patients who have passed at least 3 months after lung transplantation

Other: assessment
Evaluations of the patients will be made with scales, questionnaires and physical tests.

Outcome Measures

Primary Outcome Measures

  1. Lower extremity exercise capacity assessed by 1 minute sit to stand test (STS) [at least 3 months later post operation]

    Number of sit to stands performed by patients in 1 minute

  2. Upper Lower extremity exercise capacity assessed by 6 minutes pegboard and ring test [at least 3 months later post operation]

    the number of rings that was moved from the lower pegs to the upper pegs and vice-versa, during a six-minute period

  3. Dyspnea assessed by mMRC dyspnea scale [at least 3 months later post operation]

    modified Medical Research Council (mMRC) dyspnea scale is a self-rating tool to measure the degree of disability that breathlessness poses on day-to-day activities on a scale from 0 to 4: 0, no breathlessness except on strenuous exercise; 1, shortness of breath when hurrying on the level or walking up a slight hill; 2, walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level; 3, stops for breath after walking ∼100 m or after few minutes on the level; and 4, too breathless to leave the house, or breathless when dressing or undressing

Secondary Outcome Measures

  1. Sleep quality assessed by Pittsburgh sleep quality index [at least 3 months later post operation]

    The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction

  2. comorbidity level assessed by Charlson comorbidity index [at least 3 months later post operation]

    Charlson Comorbidity Index predicts the ten-year mortality for a patient who may have a range of comorbid conditions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • At least three months have passed since the lung transplantation, without any complications at the last doctor's control

  • Clinically stable and, if any, accompanying comorbidities are under control

  • Volunteering to participate in research

  • Patients who do not have neurological and orthopedic problems that may prevent them from performing functional tests.

Exclusion Criteria:
  • Single lung transplant recipient

  • Have orthopedic problems

  • Patients who cannot cooperate and adapt.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ankara City Hospital Ankara Turkey 06800

Sponsors and Collaborators

  • Ankara City Hospital Bilkent

Investigators

  • Principal Investigator: Erdal Yekeler, Professor, Ankara City Hospital Bilkent
  • Study Director: Ebru Calik-Kutukcu, PhD, Hacettepe University Faculty of Physical Therapy and Rehabilitation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ulaş Ar, MSc, Ankara City Hospital Bilkent
ClinicalTrials.gov Identifier:
NCT05376605
Other Study ID Numbers:
  • E2-21-52
First Posted:
May 17, 2022
Last Update Posted:
May 17, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ulaş Ar, MSc, Ankara City Hospital Bilkent

Study Results

No Results Posted as of May 17, 2022